135 related articles for article (PubMed ID: 33650041)
1. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
[TBL] [Abstract][Full Text] [Related]
2. mRNA-Expression of
Eckstein M; Wirtz RM; Gross-Weege M; Breyer J; Otto W; Stoehr R; Sikic D; Keck B; Eidt S; Burger M; Bolenz C; Nitschke K; Porubsky S; Hartmann A; Erben P
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30380731
[TBL] [Abstract][Full Text] [Related]
3. Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer.
Ottley EC; Pell R; Brazier B; Hollidge J; Kartsonaki C; Browning L; O'Neill E; Kiltie AE
J Pathol Clin Res; 2020 Oct; 6(4):238-251. PubMed ID: 32374509
[TBL] [Abstract][Full Text] [Related]
4. Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications.
Barth I; Schneider U; Grimm T; Karl A; Horst D; Gaisa NT; Knüchel R; Garczyk S
Virchows Arch; 2018 May; 472(5):749-758. PubMed ID: 29654370
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathology of the luminal class of urothelial tumors.
Bernardo C; Eriksson P; Marzouka NA; Liedberg F; Sjödahl G; Höglund M
J Pathol; 2019 Nov; 249(3):308-318. PubMed ID: 31232464
[TBL] [Abstract][Full Text] [Related]
6. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.
Breyer J; Wirtz RM; Otto W; Erben P; Worst TS; Stoehr R; Eckstein M; Denzinger S; Burger M; Hartmann A
Cancer Immunol Immunother; 2018 Mar; 67(3):403-412. PubMed ID: 29150702
[TBL] [Abstract][Full Text] [Related]
7. Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia.
Ieda T; Muto S; Shimizu F; Taguri M; Yanada S; Kitamura K; Terai K; Saito K; Ogishima T; Nagata M; Ide H; Okegawa T; Wakumoto Y; Sakamoto Y; Tsujimura A; Yamaguchi R; Nutahara K; Horie S
EBioMedicine; 2016 Oct; 12():98-104. PubMed ID: 27614395
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral Heterogeneity of Molecular Subtypes in Muscle-invasive Bladder Cancer-An Extensive Multiregional Immunohistochemical Analysis.
Schallenberg S; Dragomir MP; Anders P; Ebner B; Volz Y; Eismann L; Rodler S; Casuscelli J; Buchner A; Klauschen F; Stief C; Horst D; Schulz GB
Eur Urol Focus; 2023 Sep; 9(5):788-798. PubMed ID: 37076398
[TBL] [Abstract][Full Text] [Related]
9. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer.
Hayashi Y; Fujita K; Nojima S; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Morii E; Nonomura N
Mol Oncol; 2020 Oct; 14(10):2375-2383. PubMed ID: 32533903
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas.
Mo Q; Nikolos F; Chen F; Tramel Z; Lee YC; Hayashi K; Xiao J; Shen J; Chan KS
J Natl Cancer Inst; 2018 May; 110(5):448-459. PubMed ID: 29342309
[TBL] [Abstract][Full Text] [Related]
11. Practicability of clinical application of bladder cancer molecular classification and additional value of epithelial-to-mesenchymal transition: prognostic value of vimentin expression.
Lobo J; Monteiro-Reis S; Guimarães-Teixeira C; Lopes P; Carneiro I; Jerónimo C; Henrique R
J Transl Med; 2020 Aug; 18(1):303. PubMed ID: 32758253
[TBL] [Abstract][Full Text] [Related]
12. High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer.
Sikic D; Breyer J; Hartmann A; Burger M; Erben P; Denzinger S; Eckstein M; Stöhr R; Wach S; Wullich B; Keck B; Wirtz RM; Otto W
Transl Oncol; 2017 Jun; 10(3):340-345. PubMed ID: 28342317
[TBL] [Abstract][Full Text] [Related]
13. Preoperative fluorescence in situ hybridization analysis as a predictor of tumor recurrence in patients with non-muscle invasive bladder cancer: a bi-institutional study.
Zheng J; Lu S; Huang Y; Chen X; Zhang J; Yao Y; Cai J; Wu J; Kong J; Lin T
J Transl Med; 2023 Oct; 21(1):685. PubMed ID: 37784106
[TBL] [Abstract][Full Text] [Related]
14. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.
Lindskrog SV; Prip F; Lamy P; Taber A; Groeneveld CS; Birkenkamp-Demtröder K; Jensen JB; Strandgaard T; Nordentoft I; Christensen E; Sokac M; Birkbak NJ; Maretty L; Hermann GG; Petersen AC; Weyerer V; Grimm MO; Horstmann M; Sjödahl G; Höglund M; Steiniche T; Mogensen K; de Reyniès A; Nawroth R; Jordan B; Lin X; Dragicevic D; Ward DG; Goel A; Hurst CD; Raman JD; Warrick JI; Segersten U; Sikic D; van Kessel KEM; Maurer T; Meeks JJ; DeGraff DJ; Bryan RT; Knowles MA; Simic T; Hartmann A; Zwarthoff EC; Malmström PU; Malats N; Real FX; Dyrskjøt L
Nat Commun; 2021 Apr; 12(1):2301. PubMed ID: 33863885
[TBL] [Abstract][Full Text] [Related]
15. Positive association of collagen type I with non-muscle invasive bladder cancer progression.
Brooks M; Mo Q; Krasnow R; Ho PL; Lee YC; Xiao J; Kurtova A; Lerner S; Godoy G; Jian W; Castro P; Chen F; Rowley D; Ittmann M; Chan KS
Oncotarget; 2016 Dec; 7(50):82609-82619. PubMed ID: 27655672
[TBL] [Abstract][Full Text] [Related]
16. Lower cyclooxygenase-2 expression is associated with recurrence of solitary non-muscle invasive bladder carcinoma.
Tadin T; Krpina K; Stifter S; Babarović E; Fučkar Z; Jonjić N
Diagn Pathol; 2012 Nov; 7():152. PubMed ID: 23126361
[TBL] [Abstract][Full Text] [Related]
17. Proliferation and immunohistochemistry for p53, CD25 and CK20 in predicting prognosis of non-muscle invasive papillary urothelial carcinomas.
Kvikstad V; Lillesand M; Gudlaugsson E; Mangrud OM; Rewcastle E; Skaland I; Baak JPA; Janssen EAM
PLoS One; 2024; 19(1):e0297141. PubMed ID: 38277354
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a Natural Language Processing Model to Identify and Characterize Patients in the United States With High-Risk Non-Muscle-Invasive Bladder Cancer.
Narayan VM; Siolas D; Meadows ES; Turzhitsky V; Sillah A; Imai K; McMurry AJ; Li H
JCO Clin Cancer Inform; 2023 Sep; 7():e2300096. PubMed ID: 37906722
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy.
Hesswani C; Jackson CL; Marcq G; Hardy C; Kool R; Mansure JJ; Brimo F; Berman DM; Kassouf W
Eur Urol Open Sci; 2023 Nov; 57():22-29. PubMed ID: 38020525
[TBL] [Abstract][Full Text] [Related]
20. The impact of smoking on recurrence and progression of non-muscle invasive bladder cancer: a systematic review and meta-analysis.
Ślusarczyk A; Zapała P; Zapała Ł; Radziszewski P
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2673-2691. PubMed ID: 36404390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
